Details of Disease

General Information of Disease (ID: DISZ8MTK)

Disease Name IgA nephropathy
Synonyms segmental glomerulonephritis; IgA nephropathy; IgA Nephropathy; primary IgA nephropathy; focal glomerulonephritis; IgA glomerulonephritis; Berger's disease; Berger's IgA or IgG nephropathy
Disease Class MF8Y: Urinary system clinical sympton
Definition Inflammation of a specific segment of glomeruli within the kidney.
Disease Hierarchy
DISECBR1: Hereditary nephritis
DISPZIQ3: Glomerulonephritis
DISZ8MTK: IgA nephropathy
ICD Code
ICD-11
ICD-11: MF8Y
Expand ICD-11
'MF8Y
Disease Identifiers
MONDO ID
MONDO_0005342
MESH ID
D005922
UMLS CUI
C0017661
MedGen ID
9032
Orphanet ID
34145
SNOMED CT ID
236407003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Iptacopan DM9EZM0 Approved Small molecular drug [1]
Sparsentan DMMP51W Approved Small molecular drug [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Narsoplimab DM5KD99 Phase 3 Monoclonal antibody [3]
AVB-500 DMORJD4 Phase 2 Protein [4]
IONIS-FB-LRx DMJ2763 Phase 2 Antisense oligonucleotide [5]
LPN023 DM7BN5W Phase 2 Small molecular drug [6]
Mezagitamab DMWJXFO Phase 2 Monoclonal antibody [7]
Nefecon DMNQ9U1 Phase 2 NA [8]
RG6299 DMVJL8W Phase 2 Antisense oligonucleotide [9]
Vemircopan DM3RZ9H Phase 2 Small molecule [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 65 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
FAS TT7LTUJ Limited Therapeutic [11]
HLA-B TTGS10J Limited Genetic Variation [12]
HLA-DRB1 TTUXSTW Limited Genetic Variation [13]
MBL2 TTMQDZ5 Limited Altered Expression [14]
MMP14 TTJ4QE7 Limited Biomarker [15]
WAS TTE8T73 Limited Biomarker [16]
CYP11B2 TT9MNE2 Disputed Genetic Variation [17]
TNFSF13 TTOI1RM Disputed Biomarker [18]
CD14 TT6I7DC moderate Biomarker [19]
CD19 TTW640A moderate Altered Expression [20]
FCGR3A TTIFOC0 moderate Biomarker [19]
PDGFC TTOABM9 moderate Biomarker [21]
USP2 TTUEQ1W moderate Biomarker [22]
AGTR2 TTQVOEI Strong Genetic Variation [23]
AICDA TTKRTP6 Strong Biomarker [24]
APOL1 TTDB8PW Strong Genetic Variation [25]
AURKB TT9RTBL Strong Biomarker [26]
BACH1 TT2ME4S Strong Genetic Variation [27]
BLK TTNDSC3 Strong Genetic Variation [28]
C1QB TT8A9DM Strong Biomarker [26]
C3 TTJGY7A Strong Biomarker [29]
C5 TTKANGO Strong Biomarker [30]
C5AR1 TTHXFA1 Strong Biomarker [31]
CCL2 TTNAY0P Strong Biomarker [32]
CD163 TTTZ9DE Strong Biomarker [26]
CD37 TTFCW29 Strong Biomarker [33]
CD44 TTWFBT7 Strong Biomarker [26]
CHPF TTAZB7S Strong Biomarker [34]
ENAH TTY36UA Strong Genetic Variation [35]
EPHX2 TT7WVHI Strong Altered Expression [36]
FABP1 TTIV96N Strong Biomarker [37]
FCGRT TTKLPHO Strong Genetic Variation [38]
FOSL1 TTY8LZG Strong Biomarker [39]
FOXM1 TTD3KOX Strong Biomarker [26]
GNAO1 TTAXD8Z Strong Biomarker [40]
GPR183 TTME5YJ Strong Biomarker [26]
HLA-A TTHONFT Strong Genetic Variation [41]
HLA-DQB2 TTL7VOU Strong Biomarker [40]
HMGB2 TTA78JQ Strong Biomarker [42]
HPSE TTR7GJO Strong Biomarker [26]
IL1R2 TT51DEV Strong Genetic Variation [43]
IL5RA TTXH9AD Strong Biomarker [44]
LAIR1 TTSI7A8 Strong Biomarker [26]
LTBR TTFO0PM Strong Genetic Variation [45]
MAN2B1 TTC12RO Strong Biomarker [26]
MERTK TTO7LKR Strong Biomarker [26]
MS4A1 TTUE541 Strong Biomarker [46]
MTM1 TTY2TCU Strong Genetic Variation [47]
NLRC5 TTWZC78 Strong Biomarker [48]
NPPC TTRK0B9 Strong Altered Expression [49]
PDGFB TTQA6SX Strong Biomarker [50]
PLA2R1 TTHKW7D Strong Biomarker [51]
PSMB8 TTEAD9J Strong Genetic Variation [52]
RHO TTH0KSX Strong Altered Expression [53]
RPS6KB1 TTG0U4H Strong Altered Expression [54]
SELL TT2IYXF Strong Biomarker [55]
SMN1 TT8QL6X Strong Biomarker [56]
SYK TT2HUPM Strong Biomarker [57]
TLR1 TTW14D0 Strong Genetic Variation [58]
TLR9 TTSHG0T Strong Biomarker [18]
TNFRSF13B TTL9OD4 Strong Altered Expression [59]
TSLP TTHMW3T Strong Altered Expression [24]
UBC TTBP3XA Strong Biomarker [60]
USP14 TTVSYP9 Strong Genetic Variation [61]
PLAU TTGY7WI Definitive Therapeutic [62]
------------------------------------------------------------------------------------
⏷ Show the Full List of 65 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC3A1 DTBCKVM Strong Genetic Variation [63]
SLC43A3 DTGBPR5 Strong Biomarker [26]
------------------------------------------------------------------------------------
This Disease Is Related to 1 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
B4GALT7 DEKRS6L Strong Biomarker [64]
------------------------------------------------------------------------------------
This Disease Is Related to 100 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AGBL2 OTCX9987 Limited Biomarker [65]
B4GALT1 OTBCXEK7 Limited Biomarker [64]
EIF4G1 OT2CF1E6 Limited Biomarker [66]
MTMR3 OTBIT23O Limited Biomarker [67]
OPTN OT2UXWH9 Limited Genetic Variation [68]
ST6GAL1 OT7US3NO Limited Genetic Variation [41]
TNFRSF6B OTKAN9G7 Limited Biomarker [69]
ACCS OTHIHI9D moderate Genetic Variation [41]
CD79A OTOJC8DV moderate Genetic Variation [70]
FCGR3B OTSLSPZG moderate Biomarker [19]
HELT OTI77HDK moderate Biomarker [21]
HORMAD2 OTL2ENWI moderate Genetic Variation [52]
ITGAX OTOGIMHE moderate Genetic Variation [71]
ACOXL OTW680HT Strong Genetic Variation [12]
ACTN4 OTCNZAJ5 Strong Biomarker [72]
ACYP2 OTRB4S6X Strong Genetic Variation [73]
ADD1 OTTF68DC Strong Genetic Variation [74]
ADD2 OTRCPCD2 Strong Biomarker [75]
ANKRD16 OTZD4JUO Strong Genetic Variation [76]
ANP32B OT3SQMLU Strong Altered Expression [77]
APOBEC2 OT4CCS0Q Strong Biomarker [78]
APOM OTI3FQQC Strong Biomarker [79]
ATP6 OTPHOGLX Strong Genetic Variation [80]
AZU1 OTHXU264 Strong Genetic Variation [81]
BLNK OTSSPF6F Strong Biomarker [82]
C1QA OT6XKVVA Strong Biomarker [26]
C2 OTHMF4YM Strong Biomarker [26]
C4BPA OTHNH6Y8 Strong Biomarker [83]
C4BPB OTJ70B0K Strong Biomarker [83]
CABIN1 OT4G5CIK Strong Biomarker [84]
CARD9 OTJ81AWD Strong Genetic Variation [85]
CCL27 OTUZYC61 Strong Biomarker [86]
CCR10 OT7ZWSSD Strong Biomarker [87]
CD2AP OTC76KQM Strong Biomarker [88]
CD68 OTOYEY3J Strong Biomarker [89]
CFHR3 OTYL8SDO Strong Genetic Variation [90]
CIB2 OT9ZJX1I Strong Altered Expression [91]
CLEC14A OT0UJQ4O Strong Biomarker [92]
COL4A2 OTJK1LKN Strong Altered Expression [93]
COL4A5 OTHG60RE Strong Altered Expression [93]
CORO1C OTXDF9T3 Strong Biomarker [26]
DDN OTM52ZF5 Strong Altered Expression [94]
DEFA3 OTO3N8E1 Strong Genetic Variation [95]
DEFA5 OT95CBQ9 Strong Biomarker [52]
ECM1 OT1K65VW Strong Biomarker [81]
ELL2 OTZJRTFM Strong Altered Expression [96]
FCRL3 OTIFXFWL Strong Genetic Variation [67]
FCRLB OTL0PMQX Strong Genetic Variation [97]
FDCSP OT8KGE9M Strong Biomarker [98]
FDX1 OT7I3DN0 Strong Genetic Variation [99]
GNG2 OT05Z3MC Strong Genetic Variation [100]
GOLGA2 OT5S9KYM Strong Altered Expression [101]
HAVCR1 OT184CRZ Strong Biomarker [102]
HECW1 OT1PVAZA Strong Altered Expression [103]
HLA-DPA1 OT7OG7Y2 Strong Biomarker [104]
HLA-DPB1 OTW8JHU2 Strong Genetic Variation [105]
HLA-DQB1 OTVVI3UI Strong Biomarker [13]
HLA-DRA OT7KZMP2 Strong Biomarker [28]
IL22RA1 OTGVKLBR Strong Altered Expression [106]
JCHAIN OTR8M5TX Strong Altered Expression [107]
KIF15 OTJRJEXL Strong Biomarker [26]
LAMP3 OTN0XL3W Strong Biomarker [108]
LAPTM5 OT2XI2JG Strong Biomarker [26]
LHFPL2 OTDWEEBQ Strong Biomarker [26]
LMAN1 OTYHKDEO Strong Biomarker [109]
MAP6 OTPUI00F Strong Biomarker [110]
MEST OT8Q4U8Y Strong Genetic Variation [111]
MPDU1 OT27UPHN Strong Genetic Variation [12]
MPG OTAHW80B Strong Genetic Variation [105]
MPV17 OT579DMU Strong Genetic Variation [112]
MS4A6A OTK4BXQS Strong Biomarker [26]
MUC20 OTYYE1GK Strong Genetic Variation [113]
MX1 OT6X8G5T Strong Biomarker [114]
MYCT1 OTZ8A9L3 Strong Genetic Variation [115]
MYOM2 OTD2UOXW Strong Biomarker [116]
NPHS2 OTLCNUII Strong Altered Expression [117]
NTN4 OTDRRMP3 Strong Genetic Variation [100]
PEBP4 OTKDCVC6 Strong Biomarker [118]
PHLDB1 OTIRCB6I Strong Genetic Variation [100]
PIGR OT6GLSUL Strong Genetic Variation [119]
PLAAT4 OTI66SAJ Strong Altered Expression [120]
PPP1R15A OTYG179K Strong Altered Expression [121]
PRC1 OTHD0XS0 Strong Biomarker [26]
PXK OTSP1WLK Strong Biomarker [28]
QTRT1 OTC33MCV Strong Genetic Variation [61]
RAPGEF5 OT53VS75 Strong Genetic Variation [122]
RASGRP1 OTX9WN2E Strong Genetic Variation [123]
RGS1 OTGXJYMG Strong Genetic Variation [123]
SMN2 OT54RLO1 Strong Biomarker [56]
SPRY2 OTH0CRCZ Strong Altered Expression [124]
ST6GALNAC2 OT9PBQVT Strong Genetic Variation [125]
STAT4 OTAK3VFR Strong Genetic Variation [105]
STT3A OTDPS6AV Strong Biomarker [59]
SYNPO OTICDJAB Strong Altered Expression [126]
TIMP1 OTOXC51H Strong Biomarker [127]
TLR10 OTQ1KVJO Strong Genetic Variation [128]
TNFRSF10D OTOSRDJT Strong Biomarker [56]
TNS3 OTPG2D8Z Strong Genetic Variation [100]
CFHR1 OT72R16T Definitive Biomarker [129]
SNED1 OTBQVXY5 Definitive Altered Expression [130]
------------------------------------------------------------------------------------
⏷ Show the Full List of 100 DOT(s)

References

1 ClinicalTrials.gov (NCT04578834) Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN). U.S. National Institutes of Health.
2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216403.
3 ClinicalTrials.gov (NCT03608033) A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN). U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT04042623) Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04014335) A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy. U.S. National Institutes of Health.
6 ClinicalTrials.gov (NCT03373461) Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation. U.S. National Institutes of Health.
7 ClinicalTrials.gov (NCT05174221) A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy. U.S.National Institutes of Health.
8 ClinicalTrials.gov (NCT00767221) Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study. U.S. National Institutes of Health.
9 Clinical pipeline report, company report or official report of Roche
10 ClinicalTrials.gov (NCT05097989) A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN). U.S.National Institutes of Health.
11 Effects of Periostracum Cicadae on Cytokines and Apoptosis Regulatory Proteins in an IgA Nephropathy Rat Model.Int J Mol Sci. 2018 May 29;19(6):1599. doi: 10.3390/ijms19061599.
12 A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy.Nat Genet. 2011 Dec 25;44(2):178-82. doi: 10.1038/ng.1047.
13 DQB1*060101 may contribute to susceptibility to immunoglobulin A nephropathy in southern Han Chinese.Front Med. 2016 Dec;10(4):507-516. doi: 10.1007/s11684-016-0475-6. Epub 2016 Dec 23.
14 High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy.Nephrology (Carlton). 2019 Jul;24(7):703-710. doi: 10.1111/nep.13477. Epub 2019 Apr 23.
15 Enhanced expression of membrane type-1 matrix metalloproteinase in mesangial proliferative glomerulonephritis.J Am Soc Nephrol. 1998 Dec;9(12):2262-71. doi: 10.1681/ASN.V9122262.
16 Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency.Clin Immunol. 2012 Feb;142(2):160-6. doi: 10.1016/j.clim.2011.10.001. Epub 2011 Oct 19.
17 Association of aldosterone synthase (CYP11B2) gene -344T/C polymorphism with the risk of primary chronic glomerulonephritis in the Polish population.J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):553-8. doi: 10.1177/1470320313489588. Epub 2013 May 16.
18 TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.Kidney Int. 2020 Feb;97(2):340-349. doi: 10.1016/j.kint.2019.08.022. Epub 2019 Sep 5.
19 Elevated Numbers of Circulating Very Small Embryonic-Like Stem Cells (VSELs) and Intermediate CD14++CD16+ Monocytes in IgA Nephropathy.Stem Cell Rev Rep. 2018 Oct;14(5):686-693. doi: 10.1007/s12015-018-9840-y.
20 Increased Non-switched Memory B Cells are Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN Patients.Immunol Invest. 2020 Feb;49(1-2):178-190. doi: 10.1080/08820139.2019.1683026. Epub 2019 Oct 31.
21 PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases.J Am Soc Nephrol. 2003 May;14(5):1145-53. doi: 10.1097/01.asn.0000062964.75006.a8.
22 Expression of USP2-69 in mesangial cells in vivo and in vitro.Pathol Int. 2010 Mar;60(3):184-92. doi: 10.1111/j.1440-1827.2010.02496.x.
23 Association of angiotensin II type 2 receptor gene A1818T polymorphism with progression of immunoglobulin A nephropathy in Korean patients.J Korean Med Sci. 2009 Jan;24 Suppl(Suppl 1):S38-43. doi: 10.3346/jkms.2009.24.S1.S38. Epub 2009 Jan 28.
24 Tripterygium Wilfordii inhibits tonsillar IgA production by downregulating IgA class switching in IgA nephropathy.Oncotarget. 2017 Nov 20;8(65):109027-109042. doi: 10.18632/oncotarget.22561. eCollection 2017 Dec 12.
25 APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.J Am Soc Nephrol. 2011 Nov;22(11):1991-6. doi: 10.1681/ASN.2011040434. Epub 2011 Oct 13.
26 The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy.PLoS One. 2014 Aug 18;9(8):e103413. doi: 10.1371/journal.pone.0103413. eCollection 2014.
27 Genetic Variations rs859, rs4646, and rs372883 in the 3'-Untranslated Regions of Genes Are Associated with a Risk of IgA Nephropathy.Kidney Blood Press Res. 2019;44(2):233-244. doi: 10.1159/000498961. Epub 2019 May 8.
28 Association of systemic lupus erythematosus susceptibility genes with IgA nephropathy in a Chinese cohort.Clin J Am Soc Nephrol. 2014 Apr;9(4):788-97. doi: 10.2215/CJN.01860213. Epub 2014 Jan 23.
29 Significance of subepithelial deposits in patients diagnosed with IgA nephropathy.PLoS One. 2019 Feb 20;14(2):e0211812. doi: 10.1371/journal.pone.0211812. eCollection 2019.
30 Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.Clin Exp Immunol. 2017 Jul;189(1):60-70. doi: 10.1111/cei.12961. Epub 2017 Apr 10.
31 Respiratory Syncytial Virus Exacerbates Kidney Damages in IgA Nephropathy Mice via the C5a-C5aR1 Axis Orchestrating Th17 Cell Responses.Front Cell Infect Microbiol. 2019 May 7;9:151. doi: 10.3389/fcimb.2019.00151. eCollection 2019.
32 Value of urinary levels of interleukin-6, epidermal growth factor, monocyte chemoattractant protein type1 and transforming growth factor 1 in predicting the extent of fibrosis lesions in kidney biopsies of patients with IgA nephropathy.Nefrologia. 2017 Sep-Oct;37(5):531-538. doi: 10.1016/j.nefro.2016.11.017.
33 Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficientmice.Kidney Int. 2018 Jun;93(6):1356-1366. doi: 10.1016/j.kint.2018.01.005. Epub 2018 Mar 16.
34 Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy.Nephrol Dial Transplant. 2015 Jul;30(7):1132-9. doi: 10.1093/ndt/gfv032. Epub 2015 Mar 4.
35 The enabled homolog gene polymorphisms are associated with susceptibility and progression of childhood IgA nephropathy.Exp Mol Med. 2009 Nov 30;41(11):793-801. doi: 10.3858/emm.2009.41.11.085.
36 In vivo activity of epoxide hydrolase according to sequence variation affects the progression of human IgA nephropathy.Am J Physiol Renal Physiol. 2011 Jun;300(6):F1283-90. doi: 10.1152/ajprenal.00733.2010. Epub 2011 Mar 23.
37 Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.Nephrol Dial Transplant. 2011 Jul;26(7):2127-37. doi: 10.1093/ndt/gfq687. Epub 2010 Nov 25.
38 Association of a T-cell receptor constant alpha chain gene polymorphism with progression of IgA nephropathy in Japanese patients.Am J Kidney Dis. 1999 Aug;34(2):279-88. doi: 10.1016/s0272-6386(99)70356-2.
39 Screening and Bioinformatics Analysis of IgA Nephropathy Gene Based on GEO Databases.Biomed Res Int. 2019 Jul 16;2019:8794013. doi: 10.1155/2019/8794013. eCollection 2019.
40 Analysis of three genetic markers in IgA nephropathy patients from a single region.Clin Nephrol. 2002 Apr;57(4):253-60. doi: 10.5414/cnp57253.
41 Identification of new susceptibility loci for IgA nephropathy in Han Chinese.Nat Commun. 2015 Jun 1;6:7270. doi: 10.1038/ncomms8270.
42 Elevated hsa-miR-590-3p expression down-regulates HMGB2 expression and contributes to the severity of IgA nephropathy.J Cell Mol Med. 2019 Nov;23(11):7299-7309. doi: 10.1111/jcmm.14582. Epub 2019 Sep 26.
43 Association of genetic polymorphisms in IL-1R1 and IL-1R2 genes with IgA nephropathy in the Han Chinese population.Oncotarget. 2017 Apr 7;8(31):50673-50679. doi: 10.18632/oncotarget.16929. eCollection 2017 Aug 1.
44 Interaction of C1GALT1-IL5RA on the susceptibility to IgA nephropathy in Southern Han Chinese.J Hum Genet. 2013 Jan;58(1):40-6. doi: 10.1038/jhg.2012.133. Epub 2012 Nov 29.
45 Association between lymphotoxin beta receptor gene polymorphisms and IgA nephropathy in Korean children.Immunol Invest. 2012;41(5):447-57. doi: 10.3109/08820139.2011.649438. Epub 2012 Mar 15.
46 Plasma fractalkine levels are associated with renal inflammation and outcomes in immunoglobulin A nephropathy.Nephrol Dial Transplant. 2019 Sep 1;34(9):1549-1558. doi: 10.1093/ndt/gfy169.
47 Presence of Streptococcus mutans strains harbouring the cnm gene correlates with dental caries status and IgA nephropathy conditions.Sci Rep. 2016 Nov 4;6:36455. doi: 10.1038/srep36455.
48 NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis.J Transl Med. 2018 Nov 19;16(1):317. doi: 10.1186/s12967-018-1694-1.
49 Adrenomedullin gene transcription is decreased in peripheral blood mononuclear cells of patients with IgA nephropathy.Nephron. 2000 Jul;85(3):201-6. doi: 10.1159/000045662.
50 Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy.J Am Soc Nephrol. 1997 May;8(5):817-9. doi: 10.1681/ASN.V85817.
51 Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.J Am Soc Nephrol. 2019 Oct;30(10):2017-2026. doi: 10.1681/ASN.2018111156. Epub 2019 Aug 23.
52 Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.Nat Genet. 2014 Nov;46(11):1187-96. doi: 10.1038/ng.3118. Epub 2014 Oct 12.
53 Kidney expression of RhoA, TGF-beta1, and fibronectin in human IgA nephropathy.Nephron Exp Nephrol. 2005;101(1):e16-23. doi: 10.1159/000086035. Epub 2005 May 27.
54 The mTOR/p70S6K1 signaling pathway in renal fibrosis of children with immunoglobulin A nephropathy.J Renin Angiotensin Aldosterone Syst. 2017 Jul-Sep;18(3):1470320317717831. doi: 10.1177/1470320317717831.
55 Functional impact of IgA nephropathy-associated selectin gene haplotype on leukocyte-endothelial interaction.Immunogenetics. 2006 Jun;58(5-6):355-61. doi: 10.1007/s00251-006-0120-7. Epub 2006 Apr 28.
56 DCR2, a Cellular Senescent Molecule, Is a Novel Marker for Assessing Tubulointerstitial Fibrosis in Patients with Immunoglobulin A Nephropathy.Kidney Blood Press Res. 2019;44(5):1063-1074. doi: 10.1159/000502233. Epub 2019 Sep 5.
57 Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.Semin Nephrol. 2018 Sep;38(5):496-503. doi: 10.1016/j.semnephrol.2018.05.019.
58 TLR1 polymorphism rs4833095 as a risk factor for IgA nephropathy in a Chinese Han population: A case-control study.Oncotarget. 2016 Dec 13;7(50):83031-83039. doi: 10.18632/oncotarget.12965.
59 A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy.Cell Immunol. 2019 Jul;341:103925. doi: 10.1016/j.cellimm.2019.103925. Epub 2019 May 8.
60 Multiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network.J Intern Med. 2017 Feb;281(2):189-205. doi: 10.1111/joim.12565. Epub 2016 Oct 11.
61 Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy.Am J Hum Genet. 2002 Mar;70(3):781-6. doi: 10.1086/339077. Epub 2002 Feb 1.
62 Pathological improvement of IgA nephropathy and Henoch-Schnlein purpura nephritis with urokinase therapy.Acta Paediatr Jpn. 1996 Dec;38(6):622-8. doi: 10.1111/j.1442-200x.1996.tb03720.x.
63 Lack of Association Between Polymorphisms in AGT and ATR1 and IgA Nephropathy in a Chinese Population.Genet Test Mol Biomarkers. 2015 Dec;19(12):710-3. doi: 10.1089/gtmb.2015.0167. Epub 2015 Nov 20.
64 Development of immunoglobulin A nephropathy- like disease in beta-1,4-galactosyltransferase-I-deficient mice.Am J Pathol. 2007 Feb;170(2):447-56. doi: 10.2353/ajpath.2007.060559.
65 Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients.PLoS One. 2018 May 10;13(5):e0197219. doi: 10.1371/journal.pone.0197219. eCollection 2018.
66 Biomarker prediction for membranous nephropathy prognosis by microarray analysis.Nephrology (Carlton). 2019 May;24(5):526-533. doi: 10.1111/nep.13446.
67 Three SNPs of FCRL3 and one SNP of MTMR3 are associated with immunoglobulin A nephropathy risk.Immunobiology. 2020 Jan;225(1):151869. doi: 10.1016/j.imbio.2019.11.004. Epub 2019 Nov 18.
68 Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS/OPTN database.Transpl Int. 2018 Feb;31(2):175-186. doi: 10.1111/tri.13075. Epub 2017 Oct 12.
69 Decoy receptor 3 inhibits renal mononuclear leukocyte infiltration and apoptosis and prevents progression of IgA nephropathy in mice.Am J Physiol Renal Physiol. 2011 Dec;301(6):F1218-30. doi: 10.1152/ajprenal.00050.2011. Epub 2011 Sep 7.
70 Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort.Nephrol Dial Transplant. 2019 Oct 1;34(10):1681-1690. doi: 10.1093/ndt/gfy337.
71 Association of ITGAX and ITGAM gene polymorphisms with susceptibility to IgA nephropathy.J Hum Genet. 2019 Sep;64(9):927-935. doi: 10.1038/s10038-019-0632-2. Epub 2019 Jun 21.
72 Kidney Transplantation Outcomes across GN Subtypes in the United States.J Am Soc Nephrol. 2017 Feb;28(2):632-644. doi: 10.1681/ASN.2016020126. Epub 2016 Jul 18.
73 Association between the ACYP2 Polymorphisms and IgAN Risk in the Chinese Han Population.Kidney Blood Press Res. 2019;44(4):810-822. doi: 10.1159/000501703. Epub 2019 Jul 10.
74 The effects of both single-locus and multi-locus interaction on the clinical manifestations of IgA nephropathy in Southern Han Chinese.Nephrol Dial Transplant. 2014 Mar;29(3):550-5. doi: 10.1093/ndt/gft468. Epub 2013 Nov 21.
75 alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy.J Mol Med (Berl). 2010 Feb;88(2):203-17. doi: 10.1007/s00109-009-0549-x. Epub 2009 Oct 17.
76 Genome-wide association study identifies new susceptible loci of IgA nephropathy in Koreans.BMC Med Genomics. 2019 Aug 19;12(1):122. doi: 10.1186/s12920-019-0568-6.
77 Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy.J Am Soc Nephrol. 2017 Apr;28(4):1227-1238. doi: 10.1681/ASN.2016050496. Epub 2016 Dec 5.
78 Microarray analysis of tonsils in immunoglobulin A nephropathy patients.Biochem Biophys Res Commun. 2010 Mar 19;393(4):565-70. doi: 10.1016/j.bbrc.2010.01.120. Epub 2010 Feb 6.
79 Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology.Curr Opin Lipidol. 2019 Jun;30(3):212-217. doi: 10.1097/MOL.0000000000000606.
80 Identification of G8969>A in mitochondrial ATP6 gene that severely compromises ATP synthase function in a patient with IgA nephropathy.Sci Rep. 2016 Nov 4;6:36313. doi: 10.1038/srep36313.
81 Characterization of glomerular extracellular matrix in IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli.BMC Nephrol. 2019 Nov 14;20(1):410. doi: 10.1186/s12882-019-1598-1.
82 Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy.Clin Immunol. 2008 Mar;126(3):260-9. doi: 10.1016/j.clim.2007.11.003. Epub 2008 Jan 14.
83 Role for specific complement phenotypes and deficiencies in the clinical expression of IgA nephropathy.Am J Med Sci. 1991 Feb;301(2):115-23. doi: 10.1097/00000441-199102000-00006.
84 Successful treatment of recurrent immunoglobulin a nephropathy using steroid pulse therapy plus tonsillectomy 10years after kidney transplantation: a case presentation.BMC Nephrol. 2018 Mar 14;19(1):64. doi: 10.1186/s12882-018-0858-9.
85 The interaction effect of rs4077515 and rs17019602 increases the susceptibility to IgA nephropathy.Oncotarget. 2017 Aug 23;8(44):76492-76497. doi: 10.18632/oncotarget.20401. eCollection 2017 Sep 29.
86 Tonsillitis exacerbates renal injury in IgA nephropathy through promoting Th22 cells chemotaxis.Int Urol Nephrol. 2018 Jul;50(7):1285-1292. doi: 10.1007/s11255-018-1792-2. Epub 2018 Mar 16.
87 Intrinsic renal cells induce lymphocytosis of Th22 cells from IgA nephropathy patients through B7-CTLA-4 and CCL-CCR pathways.Mol Cell Biochem. 2018 Apr;441(1-2):191-199. doi: 10.1007/s11010-017-3185-8. Epub 2017 Sep 5.
88 Inhibition of miRNA-21 prevents fibrogenic activation in podocytes and tubular cells in IgA nephropathy.Biochem Biophys Res Commun. 2014 Feb 21;444(4):455-60. doi: 10.1016/j.bbrc.2014.01.065. Epub 2014 Jan 24.
89 Relationship between renal CD68(+) infiltrates and the Oxford Classification of IgA nephropathy.Histopathology. 2019 Mar;74(4):629-637. doi: 10.1111/his.13768. Epub 2019 Jan 15.
90 Variation in complement factor H affects complement activation in immunoglobulin A vasculitis with nephritis.Nephrology (Carlton). 2020 Jan;25(1):40-47. doi: 10.1111/nep.13580. Epub 2019 May 5.
91 Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human IgA nephropathy.J Am Soc Nephrol. 2004 Jan;15(1):79-90. doi: 10.1097/01.asn.0000104573.54132.2e.
92 A candidate gene approach to genetic contributors to the development of IgA nephropathy.Nephrol Dial Transplant. 2012 Mar;27(3):1020-30. doi: 10.1093/ndt/gfr369. Epub 2011 Jul 7.
93 Glomerular expression of alpha2(IV) and alpha5(IV) chains of type IV collagen in patients with IgA nephropathy.Nephron. 2002 May;91(1):43-50. doi: 10.1159/000057603.
94 Expression of DENDRIN in several glomerular diseases and correlation to pathological parameters and renal failure - preliminary study.Diagn Pathol. 2018 Nov 20;13(1):90. doi: 10.1186/s13000-018-0767-z.
95 Low -defensin gene copy number increases the risk for IgA nephropathy and renal dysfunction.Sci Transl Med. 2016 Jun 29;8(345):345ra88. doi: 10.1126/scitranslmed.aaf2106.
96 ELL2 Is Downregulated and Associated with Galactose-Deficient IgA1 in IgA Nephropathy.Dis Markers. 2019 Jun 4;2019:2407067. doi: 10.1155/2019/2407067. eCollection 2019.
97 FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy.PLoS One. 2013 Apr 12;8(4):e61208. doi: 10.1371/journal.pone.0061208. Print 2013.
98 Decreased expression of follicular dendritic cell-secreted protein correlates with increased immunoglobulin A production in the tonsils of individuals with immunoglobulin A nephropathy.Transl Res. 2015 Sep;166(3):281-91. doi: 10.1016/j.trsl.2015.04.004. Epub 2015 Apr 17.
99 Association between CCDC132, FDX1 and TNFSF13 gene polymorphisms and the risk of IgA nephropathy.Nephrology (Carlton). 2015 Dec;20(12):908-15. doi: 10.1111/nep.12611.
100 3'UTR variants of TNS3, PHLDB1, NTN4, and GNG2 genes are associated with IgA nephropathy risk in Chinese Han population.Int Immunopharmacol. 2019 Jun;71:295-300. doi: 10.1016/j.intimp.2019.03.041. Epub 2019 Mar 28.
101 Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy.Am J Nephrol. 2019;49(4):307-316. doi: 10.1159/000499110. Epub 2019 Mar 27.
102 Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression.Am J Kidney Dis. 2020 Mar;75(3):384-393. doi: 10.1053/j.ajkd.2019.07.018. Epub 2019 Oct 9.
103 Changes E3 ubiquitin protein ligase 1 gene mRNA expression correlated with IgA1 glycosylation in patients with IgA nephropathy.Ren Fail. 2019 Nov;41(1):370-376. doi: 10.1080/0886022X.2019.1605295.
104 HLA-DP region gene polymorphism in primary IgA nephropathy: no association.Nephrol Dial Transplant. 1992;7(3):200-4. doi: 10.1093/oxfordjournals.ndt.a092105.
105 Genetic polymorphisms in HLA-DP and STAT4 are associated with IgA nephropathy in a Southwest Chinese population.Oncotarget. 2018 Jan 2;9(6):7066-7074. doi: 10.18632/oncotarget.23829. eCollection 2018 Jan 23.
106 A polymorphism of interleukin-22 receptor alpha-1 is associated with the development of childhood IgA nephropathy.J Interferon Cytokine Res. 2013 Oct;33(10):571-7. doi: 10.1089/jir.2012.0097. Epub 2013 May 9.
107 Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA.J Clin Pathol. 1996 Jan;49(1):38-42. doi: 10.1136/jcp.49.1.38.
108 Clinical and immunological implications of increase in CD208+ dendritic cells in tonsils of patients with immunoglobulin A nephropathy.Nephrol Dial Transplant. 2013 Dec;28(12):3004-13. doi: 10.1093/ndt/gft399. Epub 2013 Sep 29.
109 IgA nephropathy-specific expression of the IgA Fc receptors (CD89) on blood phagocytic cells.Clin Exp Immunol. 1997 Nov;110(2):226-32. doi: 10.1111/j.1365-2249.1997.tb08321.x.
110 CTLA-4 Polymorphisms in Patients with IgA Nephropathy Correlate with Proteinuria.Kidney Blood Press Res. 2018;43(2):360-366. doi: 10.1159/000488069. Epub 2018 Mar 8.
111 Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy.Sci Rep. 2017 Apr 24;7(1):1100. doi: 10.1038/s41598-017-01223-3.
112 Crescents and Global Glomerulosclerosis in Chinese IgA Nephropathy Patients: A Five-Year Follow-Up.Kidney Blood Press Res. 2019;44(1):103-112. doi: 10.1159/000498874. Epub 2019 Feb 22.
113 Tandem repeats polymorphism of MUC20 is an independent factor for the progression of immunoglobulin A nephropathy.Am J Nephrol. 2006;26(1):43-9. doi: 10.1159/000091785. Epub 2006 Feb 24.
114 Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-nave lupus nephritis, but not in those under immunosuppressive treatment.Mod Rheumatol. 2018 Jul;28(4):661-669. doi: 10.1080/14397595.2017.1404711. Epub 2017 Nov 30.
115 Novel genes and variants associated with IgA nephropathy by co-segregating with the disease phenotypes in 10 IgAN families.Gene. 2015 Oct 15;571(1):43-51. doi: 10.1016/j.gene.2015.06.041. Epub 2015 Jun 18.
116 Streptococcal M protein enhances TGF-beta production and increases surface IgA-positive B cells in vitro in IgA nephropathy.Nephrol Dial Transplant. 2000 Jun;15(6):772-7. doi: 10.1093/ndt/15.6.772.
117 Sorting Nexin 9 facilitates podocin endocytosis in the injured podocyte.Sci Rep. 2017 Mar 7;7:43921. doi: 10.1038/srep43921.
118 Phosphatidylethanolamine binding protein-4 (PEBP4) is increased in IgA nephropathy and is associated with IgA-positive B-cells in affected kidneys.J Autoimmun. 2019 Dec;105:102309. doi: 10.1016/j.jaut.2019.102309. Epub 2019 Aug 9.
119 Association of single-nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy (IgAN) in Japanese patients.J Hum Genet. 2003;48(6):293-299. doi: 10.1007/s10038-003-0027-1. Epub 2003 May 10.
120 Expressions of mRNA for innate immunity-associated functional molecules in urinary sediment in immunoglobulin A nephropathy.Nephrology (Carlton). 2015 Dec;20(12):916-21. doi: 10.1111/nep.12533.
121 Impact of GADD34 on Apoptosis of Tonsillar Mononuclear Cells from IgA Nephropathy Patients by Regulating Eif2 Phosphorylation.Cell Physiol Biochem. 2018;50(6):2203-2215. doi: 10.1159/000495061. Epub 2018 Nov 9.
122 T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target.Clin Exp Nephrol. 2019 Mar;23(3):291-303. doi: 10.1007/s10157-018-1665-0. Epub 2018 Nov 7.
123 Novel identified associations of RGS1 and RASGRP1 variants in IgA Nephropathy.Sci Rep. 2016 Nov 2;6:35781. doi: 10.1038/srep35781.
124 A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. Eur J Hum Genet. 2015 Dec;23(12):1673-8. doi: 10.1038/ejhg.2015.52. Epub 2015 Mar 18.
125 Interaction between variants of two glycosyltransferase genes in IgA nephropathy.Kidney Int. 2009 Jul;76(2):190-8. doi: 10.1038/ki.2009.99. Epub 2009 Apr 8.
126 Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy.Nephrol Dial Transplant. 2009 Jan;24(1):62-72. doi: 10.1093/ndt/gfn441. Epub 2008 Aug 6.
127 Analysis of the differential urinary protein profile in IgA nephropathy patients of Uygur ethnicity.BMC Nephrol. 2018 Dec 14;19(1):358. doi: 10.1186/s12882-018-1139-3.
128 Association between toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy.Eur J Pediatr. 2011 Apr;170(4):503-9. doi: 10.1007/s00431-010-1325-1. Epub 2010 Oct 16.
129 Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation inIgA nephropathy.Kidney Int. 2017 Oct;92(4):953-963. doi: 10.1016/j.kint.2017.03.041. Epub 2017 Jun 19.
130 Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.J Histochem Cytochem. 2008 Aug;56(8):733-43. doi: 10.1369/jhc.2008.950998. Epub 2008 Apr 28.